• Explore /
  • Poster
  • / Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).

Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).

Abstract Poster

Authors

null

Johanna C. Bendell

Sarah Cannon Research Institute, Nashville, TN

Johanna C. Bendell , Chloe Evelyn Atreya , Thierry André , Josep Tabernero , Michael S. Gordon , Rene Bernards , Eric Van Cutsem , Sabine Tejpar , Roger Sidhu , William Y. Go , Alicia Allred , Monica Motwani , Benjamin B. Suttle , Yuehui Wu , Axel Hoos , Keith W. Orford , Ryan Bruce Corcoran , Jan HM Schellens

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Highlights Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer

Clinical Trial Registration Number

NCT01750918

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 3515)

DOI

10.1200/jco.2014.32.15_suppl.3515

Abstract #

3515

Poster Bd #

3

Abstract Disclosures

Similar Posters

First Author: Ryan Bruce Corcoran

First Author: Morten Mau-Soerensen

First Author: April K.S. Salama

First Author: Gregory J. Riely